Letter

Disappointing article, not disappointing biotech

BMJ 2005; 331 doi: 10.1136/bmj.331.7523.1025 (Published 27 October 2005)
Cite this as: BMJ 2005;331:1025.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fredric J Cohen, president (fred@pharmagrowth.com)
  1. Pharma Growth Strategies LLC, 3331 Street Road, Suite 140, Bensalem, PA 19020, USA

    EDITOR—Joppi et al's critique and not biotech itself is disappointing.1

    The authors classified most of the biotech drugs (24/61) as “copycat or me too products”—pejorative terms intended to cast prejudicial doubt on a drug's value. I am familiar with one of the drugs on the copycat list, teriparatide (rhPTH1-34, Forteo, Eli Lilly), a treatment for osteoporosis. I helped …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular